LOTTE BIOLOGICS Participates in CPhI Worldwide 2023,

Strengthening Global Partnerships

■ Aligning with the event's theme of 'Sustainability,' the company utilizes eco-friendly materials for booth construction
■ Plans to proactively pursue CDMO business leveraging synergies between the Syracuse site and Songdo mega plants

LOTTE BIOLOGICS, led by CEO Richard Lee, has announced its participation in CPhI Worldwide 2023, taking place over three days from October 24 to 26 in Barcelona, Spain.

Initially launched in 1990, CPhI is the world's largest pharmaceutical and bio-conference, commencing in one of the select cities across the globe each year. The event offers exhibitions, seminars, and other side activities, all contributing to the global advancement of the pharmaceutical and biotech industries. This year’s CPhI Worldwide theme is 'Sustainability,' with various policies in place to minimize environmental impact, including the use of ▲100% renewable energy, ▲minimization of disposable exhibition booths through the Better Stands Program, and ▲reduction of single-use plastics, to mitigate environmental impact.

For the second consecutive year, LOTTE BIOLOGICS has taken part with a dedicated booth designed in line with the event's sustainability theme. Utilizing reusable, eco-friendly metal frames, light panels, and digital signage, the company aims not only to showcase its commitment to environmental sustainability but also to introduce its differentiated competitive advantages. These include mid-to-long-term business strategies anchored by our Syracuse facility in the U.S. and mega plants in Korea, Bio-Venture Initiative creation, and ADC technology platform capabilities. We are particularly emphasizing the expansion of our service offerings by including 3,000L stainless steel bioreactors (8EA) within our Plant 1 at our Songdo Mega Plant Site, Korea to meet the high-titer products demand.

The booth will also feature a meeting table and two private meeting rooms to facilitate scheduled meetings with major global pharmaceutical companies and various biotech organizations.

Kyoungeun Kim, the Chief Business Officer of LOTTE BIOLOGICS, said, “Ever since we announced the construction of our 360,000-liter mega plant in Incheon's Songdo International City, we’ve seen continued interest from potential clients regarding our completion timelines and production capabilities.” She added, “We plan to aggressively expand our CDMO business, drawing on the synergies between our acquired Syracuse site and the upcoming Songdo mega plants.”

Previously, LOTTE BIOLOGICS participated in both the BIO International Convention 2023 in June and BIO Japan 2023 in October, operating dedicated booths and establishing in-depth partnerships with global pharmaceutical firms and small-to-medium biotech companies.